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The role of MRI differs considerably between the three main groups of hematological malignancies: lymphoma, leukemia,
and myeloma. In myeloma, whole-body MRI (WB-MRI) is recognized as a highly sensitive test for the assessment of mye-
loma, and is also endorsed by clinical guidelines, especially for detection and staging. In lymphoma, WB-MRI is presently
not recommended, and merely serves as an alternative technique to the current standard imaging test, [18F]FDG-PET/CT,
especially in pediatric patients. Even for lymphomas with variable FDG avidity, such as extranodal mucosa-associated lym-
phoid tissue lymphoma (MALT), contrast-enhanced computed tomography (CT), but not WB-MRI, is presently rec-
ommended, despite the high sensitivity of diffusion-weighted MRI and its ability to capture treatment response that has
been reported in the literature. In leukemia, neither MRI nor any other cross-sectional imaging test (including positron
emission tomography [PET]) is currently recommended outside of clinical trials. This review article discusses current clinical
applications as well as the main research topics for MRI, as well as PET/MRI, in the ﬁeld of hematological malignancies,
with a focus on functional MRI techniques such as diffusion-weighted imaging and dynamic contrast-enhanced MRI, on the
one hand, and novel, non-FDG PET imaging probes such as the CXCR4 radiotracer [68Ga]Ga-Pentixafor and the amino acid
radiotracer [11C]methionine, on the other hand.
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IMAGING OF HEMATOLOGICAL MALIGNANCIES,which account for about 10% of all newly diagnosed can-
cers in the United States, is a complex topic. Despite their
common origin—the hematopoietic and lymphoid tissues—
there is a high level of heterogeneity within this group of can-
cers, and even within its three main subgroups: lymphoma
(48% of all new cases), leukemia (35% of all new cases), and
myeloma (18% of all new cases; also known as plasma cell
disorders).1 This heterogeneity does not only affect prognosis
and choice of treatment, but also choice of imaging technique
and imaging features.
The role of imaging as part of the clinical workup is also
fundamentally different between the three main groups of
hematological malignancies. While imaging is the main tool for
staging as well as treatment response assessment in
lymphoma,2–4 it represents one of several key criteria for the diag-
nosis and follow-up of myeloma5; whereas in leukemia, imaging
(and even more so, cross-sectional techniques such as magnetic
resonance imaging [MRI]) is presently just an adjunct test of
questionable clinical relevance outside of clinical trials.6–9
Computed tomography (CT),MRI, and positron emission
tomography (PET) using the radiotracer [18F]FDG (2-[18F]-
ﬂuoro-2-deoxy-D-glucose) have very different applications in
hematological malignancies; generally, while CT and PET/CT
clearly dominate imaging of lymphomas,2–4 in myeloma whole-
body (WB-)MRI and [18F]FDG-PET/CT are of similar
View this article online at wileyonlinelibrary.com. DOI: 10.1002/jmri.26848
Received Mar 26, 2019, Accepted for publication Jun 17, 2019.
*Address reprint requests to: M.E.M., Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065.
E-mail: mayerhom@mskcc.org
From the 1Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Austria;
2Department of Radiology, Memorial Sloan Kettering Cancer Center New York, New York, USA; 3PET Research Centre, University of Hull, UK; 4Department of
Radiology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK; and 5Department of Biomedical Imaging and Image-guided Therapy, Division
of Nuclear Medicine, Medical University of Vienna, Austria
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
© 2019 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc.
on behalf of International Society for Magnetic Resonance in Medicine.
1
importance, but used for different clinical questions.5 Regardless of
the type of hematological cancer, the lack of exposure to ionizing
radiation with MRI could represent an advantage in pediatric
patients who may require life-long follow-up. Reduced radiation
exposure relative to PET/CT, but mainly the possibility to obtain
truly multiparametric information that may potentially improve
treatment response assessment and outcome prognostication, are
the arguments in favor of the novel hybrid imaging test, PET/MRI.
The aim of this article is to review the current imaging
state-of-the-art in the three main groups of hematological
malignancies, with a special focus on the role of MRI, alone
or in combination with PET, and to discuss its possible
future applications.
MRI and PET/MRI Protocols for Hematological
Malignancies
MRI Pulse Sequences for Whole-Body Imaging
In systemic diseases such as hematological malignancies that
lack a true "primary" tumor, whole-body sequences represent
the backbone of MRI. The most commonly used whole-body
MR sequences for cancer imaging are:
1. a STIR or fat-saturated T2-weighted sequence, in the coro-
nal (for lymphoma) and/or sagittal (for myeloma) plane;
2. an axial 3D gradient-echo Dixon or fast spin-echo T1-
weighted sequence with multiplanar reconstructions;
3. an axial diffusion-weighted imaging (DWI) sequence,
obtained during free breathing and with background sup-
pression, utilizing SPIR- or STIR-based techniques; at
least two b-values (0–50; and 800–1000) should be used;
4. a fast spin-echo T2-weighted sequence (such as half-
Fourier acquisition single shot / half-acquisition turbo
spin-echo [HASTE]) in the coronal or axial plane.
DWI, in which the imaging signal depends on the degree
of compression of extracellular space due to cell enlargement and
increased cell density in tumor tissue, has become especially pop-
ular due to its high lesion-to-background contrast and its ability
to quantify treatment-induced changes in diffusivity through cal-
culation of apparent diffusion coefﬁcients (ADCs). Increased dif-
fusivity onDWI as reﬂected by an ADC increase has been shown
to correspond to treatment-induced cell death (necrosis) in mela-
noma as well as colon cancer xenografts.10,11 Although limited
by some technical artifacts—especially in the mediastinum,
where the combination of cardiac and respiratory motion repre-
sents a challenge; and in the lower neck, where RF ﬁeld inhomo-
geneity is frequently observed—DWI has largely replaced
gadolinium-based contrast-enhanced (CE-) T1-weighted
sequences for whole-body imaging of hematological malignancies
in clinical practice. This is because CE-MRI does not appear to
have clear advantages over unenhanced MR sequences in terms
of lesion detection or staging12,13—eg, in the study by Arendt
et al,13 agreement between unenhanced and contrast-enhanced
MRI for lymph node assessment was high, with κ = 0.81—but
introduces the small but recognized risk of contrast media side
effects, and even nephrogenic systemic ﬁbrosis in patients with
impaired renal function,14 as is common in myeloma. The
risk introduced by gadolinium deposits in the brain is currently
being investigated.15 Nevertheless, CE-MRI is still being rec-
ommended as an alternative to CE-CT inmany clinical trials.
PET Radiotracers
There is no doubt that the radiolabeled glucose analog [18F]FDG
is the dominant radiotracer for PET imaging of hematological
malignancies (see Lymphoma and Myeloma sections, below).
Nevertheless, alternative tracers to [18F]FDG have been investi-
gated, mainly to differentiate tumor tissue from inﬂammation, or
to predict therapy response, but also to improve image quality in
areas of high [18F]FDG uptake such as the central nervous system
(CNS). These include the cellular proliferation tracer [18F]FLT
(3-[18F]-ﬂuoro-3-deoxythymidine), which has mainly been
applied posttreatment, and appears to be effective in differentiat-
ing residual lymphoma from areas of inﬂammation. There are
also studies indicating that pretreatment imaging with [18F]FLT
could be a predictor of survival and of therapy response to CD20
targeting monoclonal antibody treatments (eg, rituximab).16,17
There has been interest in the use of the radiolabeled
amino acid [11C]methionine (L-methyl-[11C]-methionine) in
hematological malignancies, as it can, for instance, delineate
CNS lymphoma due to the low uptake in normal brain com-
pared with [18F]FDG, and changes in tracer uptake have been
detected postradiotherapy.18 [11C]methionine has increased
cellular uptake in neoplasms via the large amino acid trans-
porter (LAT1). In a study in pediatric lymphoma, both
Hodgkin’s and non-Hodgkin lymphomas were effectively
visualized, although high physiologic activity in liver and
bone marrow was a major limitation.19
Chemokine receptor-targeted PET is another highly inter-
esting approach for imaging of hematological malignancies.
Chemokines are signaling molecules that bind to chemokine
receptors on the surface of immune cells, which migrate in
response to the increasing chemokine concentration gradient.
CXCR4 is a member of this family of receptors; it is involved in
organogenesis at the embryonic stage and has many other physio-
logical roles; importantly, the receptor also has a role in tumori-
genesis in some cancers, enhancing proliferation, migration, and
invasion.20 Clinically, CXCR4 PET imaging has been shown to
be feasible in leukemia, lymphoma, and multiple myeloma, as
well as some solid tumors. For instance, [68Ga]Ga-Pentixafor has
been developed as a cyclic peptide imaging agent with DO3A
(1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid) chelated
gallium-68 with imaged receptor expression levels acting as a
prognostic marker.21 In multiple myeloma (MM) and leukemia,
CXCR4 overexpression in terms of pathologically increased
uptake was observed in about two-thirds of patients imaged.22–24
This agent has been used to image therapy response, for example
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in a patient with extranodal marginal zone lymphoma of the
orbital cavities.25 There are, however, challenges with dynamic
and variable CXCR4 expression levels, indicating that further
investigation of the receptor biology is required to fully under-
stand the prognostic value and therapy response data. Small mol-
ecule alternatives to the peptidic agent, radiolabeled with either
copper-64 or gallium-68, are undergoing preclinical evaluation
and are likely to have future clinical impact.26–28
Lymphoma
Overview and Current Recommendations for
Imaging
Lymphomas represent the group of hematological malignancies
with the highest prevalence and incidence,1 and arguably also the
highest degree of heterogeneity in terms of histology and progno-
sis. Based on their histological features, they can be divided into
B-cell andT/NK (natural killer)-cell lymphomas on the one hand,
andHodgkin (HL) and non-Hodgkin (NHL) lymphomas on the
other hand. In addition, the REAL classiﬁcation that very roughly
subdivides these neoplasms into fast- and very fast-growing
"aggressive" and slowly-growing but incurable "indolent" sub-
types is also still widely used.29 Notably, histology is not just
important for assessment of prognosis and treatment decisions—
for instance, HL has a long-term cure rate of up to 90%with stan-
dard chemotherapy regimens30—but also imaging.
For the initial detection of lymphoma, imaging is fre-
quently used early on in the diagnostic workup: enlarged pal-
pable superﬁcial lymph nodes (eg, of the neck, axilla, or
groin) are often evaluated by ultrasound sonography ahead of
more speciﬁc laboratory tests, to determine the extent, mor-
phology, and likelihood of malignancy. Depending on the
anatomic location of the lymph node or mass, CT or
ultrasound-guided biopsies may also be performed instead of
surgical resection to establish the diagnosis.
For both staging and treatment response assessment, [18F]
FDG-PET/CT is considered the technique of choice for the vast
majority of lymphoma subtypes, according to the guidelines of
the International Conference on Malignant Lymphoma
(ICML), because they show a high glucose metabolism.2,3 These
FDG-avid lymphomas include HL, diffuse large B-cell lym-
phoma (DLBCL) as the most common aggressive NHL (33%),
and follicular lymphoma (FL) as the most common indolent
NHL (25%). However, other lymphoma subtypes such as the
family of marginal zone lymphomas (MZL), of which extranodal
mucosa-associated lymphoid tissue lymphoma (MALT) is the
most common representative, are not reliably FDG-avid,3,31,32 at
least when PET is performed at the standard timepoint (ie, 60 min)
after tracer injection. For such lymphoma subtypes, the ICML pres-
ently recommends the use of contrast-enhanced CT, rather than
MRI or [18F]FDG-PET,3 for both staging and treatment response
assessment, despite the fact that, at least in MALT lymphoma,
[18F]FDG-PET has been shown to predict survival.33,34
Treatment response assessment—arguably the most rel-
evant task for imaging tests in lymphoma patients from a
clinical point of view—is currently based on the Lugano
classiﬁcation,2,3 or alternatively, the more novel RECIL classi-
ﬁcation.4 Both response classiﬁcation systems share the same
approach for evaluation of [18F]FDG-PET: the semiquantita-
tive 5-point Deauville scale that is based on comparison of
the posttherapeutic [18F]FDG uptake (maximum standard-
ized uptake, SUVmax) of lesions compared with that of the
liver, and, of lesser importance, the mediastinal blood pool.
Any uptake higher than that of the liver (Deauville scores
4 and 5) is considered residual disease, regardless of lesion
size. To achieve complete remission, on the other hand,
Deauville scores 1–3 (uptake equal to, or less than the liver)
is required2–4; and with RECIL, an additional ≥30% decrease
in tumor size.4
Notably, many previous studies have also shown that
pretherapeutic SUVs, metabolic tumor volumes (MTV), and total
lesion glycolysis (TLG) extracted from [18F]FDG-PET enable out-
come prognostication in a variety of histological subtypes, includ-
ing HL, DLBCL, FL, and also T-cell lymphomas.35–40 In
addition, [18F]FDG-PET has also been evaluated as a tool for risk
stratiﬁcation in clinical trials,41,42 and several studies to investigate
this topic are still ongoing.
MRI is currently only recommended by the guidelines
for speciﬁc scenarios: assessment of suspected lymphomatous
CNS involvement, where CE-MRI is the established standard
of care; and assessment of primary bone involvement,3,4 or
when minimization of exposure to ionizing radiation is desir-
able4; for instance, in pediatric patients. PET/MRI is cur-
rently not included in the Lugano or RECIL guidelines.
Research Applications and Future Directions for
MRI and PET/MRI
A substantial number of comparative studies in FDG-avid lym-
phomas have shown good agreement between WB-MRI and
[18F]FDG-PET/CT in terms of lesion assessment and staging,
most of them reporting an overall small-to-moderate inferiority
for WB-MRI.43–48 For instance, Abdulqadr et al reported identi-
cal staging for DWI and [18F]FDG-PET/CT in 90.3%,43
whereas in a study by van Ufford et al, agreement in terms of
staging was only 77%,44 in mixed lymphoma populations,
respectively. In our own study, concordance with a reference
standard that relied chieﬂy on [18F]FDG-PET/CT was observed
in 94% of patients with FDG-avid lymphoma subtypes.45 How-
ever, in patients with lymphomas with variable FDG avidity (eg,
MALT lymphoma and small lymphocytic lymphoma [SLL]) (see
Fig. 1), WB-MRI with/without DWI has proven to be superior
to both [18F]FDG-PET/CT and the ofﬁcially recommended
standard technique, CE-CT43,45,49—in the largest study so far,
with staging accuracies of 92.5%, 65%, and 60% for WB-DWI,
PET/CT and CE-CT, respectively.45 The drawbacks of WB-
DWI are imaging of the mediastinum and the head/neck region
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(which are typical sites of involvement in lymphoma patients)
due to artifacts, as discussed above; and also the fact that small
inﬂammatory lymph nodes frequently show a diffusion restric-
tion pattern.45,50 No generally accepted ADC cutoff has been
established to distinguish inﬂammatory from malignant lymph
nodes so far, and thus, the established morphological criterion of
1.5 cm long axis diameter, or novel techniques such as histogram
analyses,50 may need to be taken into account (see Fig. 2).
Despite the known strength of MRI for bone marrow assess-
ment, neither T1-weighted MRI nor DWI enabled reliable
assessment of diffuse marrow inﬁltration in previous studies.51,52
Asenbaum et al reported that, while sensitivity was reasonably
good (87.5%) when using a ﬁxed ADC cutoff, speciﬁcity for dif-
fuse bonemarrow involvement was poor, with only 57%.51
WB-MRI has also shown good sensitivity and speciﬁcity for
response assessment of lymphomas, especially when including
DWI, with results that are only slightly inferior to those of [18F]
FDG-PET/CT in the majority of studies.53–55 In one study,
Maggialetti et al reported a concordance of WB-MRI/DWI with
[18F]FDG-PET/CT in 94% of their patients who were classiﬁed
as showing either treatment response or no response55; whereas in
a different study that used the classic treatment response categories
of complete remission, partial remission, stable disease, and pro-
gressive disease, agreement between the two techniques was
97%.54 Contrary to morphological MRI sequences, and similar
to [18F]FDG-PET, DWI has been shown to enable (semi)quanti-
tative assessment of treatment effects as early as 48–72 hours after
treatment initiation in lymphomas.56 However, while it is gener-
ally recognized that ADCs reﬂect treatment response per se, no
ADC cutoff values are presently established for separating partial
from complete response, which is of high clinical signiﬁcance, and
there is also no MRI-based scoring system comparable to the
Deauville score (ie, no reference tissue deﬁnitions). Therefore,
since [18F]FDG-PET/CT is currently so well established as the
imaging technique of choice for response assessment, WB-MRI
may need to establish its role in clinical situations where PET/CT
is currently not recommended in clinical routine, such as in the
monitoring of lymphoma patients who have achieved complete
remission, or in patients with indolent NHL subtypes that
undergo "watchful waiting"—a recent publication showed that
WB-MRI seems to be well suited for this task.57
Comparing [18F]FDG-PET/MRI and PET/CT, a limited
number of studies have either suggested a similar performance of
the two techniques,58–61 and in lymphomas with variable FDG
avidity a superiority of PET/MRI over PET/CT for disease detec-
tion.62,63 Furthermore, due to the longer examination time of
PET/MRI, dual timepoint [18F]FDG-PET may be more easily
implemented for patients with indolent, variably FDG-avid lym-
phomas such as MALT, whose visualization is possibly improved
by prolonged radiotracer uptake time in the tumor and concur-
rent tracer washout from surrounding tissues.64 In pediatric lym-
phoma patients, [18F]FDG-PET/MRI performed moderately
better than WB-MRI (with diagnostic accuracies of 96–97%
vs. 86%, respectively), which is frequently used as a radiation-free
FIGURE 1: A 62-year-old patient with small-cell lymphocytic lymphoma (SLL). The paraaortic nodal manifestations (blue arrows) show
only very subtle [18F]FDG uptake on PET, whereas they show a clearly restricted diffusivity, with high signal on the b-800 DWI and
low signal on the corresponding ADC map. The color-coded b-800 DWI fused with T1-weighted images enable better anatomic
localization of the lesions, similar to fused PET/CT images.
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alternative imaging test in this age group.65 Since no study on
[18F]FDG-PET/MRI in lymphomas has suggested an inferiority
of the technique relative to PET/CT (or WB-MRI), it would
seem reasonable to include PET/MRI as an alternative to
PET/CT in management guidelines, at least for certain
populations.Whether PET/MRI has advantages over PET/CT in
terms of treatment response assessment and outcome
prediction—for instance, by combining SUV and ADCmeasure-
ments, or PET andDWI radiomic features—is presently unclear.
Myeloma
Overview and Current Recommendations for
Imaging
Of the three large families of hematological malignancies,
myeloma is the one with the overall poorest prognosis.66
Characterized by clonal proliferation of plasma cells and asso-
ciated proteins, myeloma has three consecutive stages: the
precursor condition, termed monoclonal gammopathy of
undetermined signiﬁcance (MGUS); the asymptomatic smol-
dering myeloma (SM); and the symptomatic MM, or
plasmacytoma in case of single-site involvement.
While the diagnosis of the asymptomatic MGUS and SM
are purely based on laboratory ﬁndings in the blood and urine,67
the International Myeloma Working Group’s (IMWG) updated
criteria for the diagnosis of MM include any M-spike or urinary
M protein, clonal bone marrow plasma cell inﬁltration >10%, or
biopsy-proven bony or extramedullary plasmacytoma, and one
or more of the following myeloma-deﬁning events (the so-called
CRAB criteria)5:
1. Hypercalcemia
2. Renal insufﬁciency
3. Anemia
4. Osteolytic bone lesions, as depicted on skeletal radiogra-
phy, CT, or [18F]FDG-PET/CT;
OR one of the following biomarkers of malignancy:
1. Clonal bone marrow plasma cell percentage of at
least 60%
2. Involved-to-uninvolved serum free light chain ratio of at
least 100
3. More than one focal lesion on MRI with 5 mm diameter.
Therefore, imaging tests play an important role for esta-
blishing the diagnosis of MM, although no single cross-sectional
imaging test is preferred. This contrasts with national guidelines
from the British Society of Haematology as well as NICE,
according to whichWB-MRI is preferred as the ﬁrst-line imaging
test for suspected and newly diagnosed myeloma.68,69 Notably,
unlike CT and PET/CT, the IMWG lists MRI as a "biomarker,"
albeit without providing details on the type(s) of MRI sequences
that should be used. With regard to the comparative perfor-
mances of WB-MRI and [18F]FDG-PET/CT, the IMWG states
that MRI is the best technique for detection of diffuse marrow
FIGURE 2: A 42-year-old patient referred with a clinical suspicion of lymphoma. [18F]FDG-PET is negative, whereas DWI shows
several small cervical lymph nodes with a long axis diameter <1.5 cm (blue arrows) that show a moderately restricted diffusivity, and
which were proven to be inﬂammatory.
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involvement, whereas [18F]FDG-PET/CT is recommended to
distinguish active MM from SM; in addition, [18F]FDG
PET/CT at the onset of MM is endorsed because it may have
prognostic value.5 While the guidelines state that [18F]FDG-
PET/CT should be considered the preferred imaging technique
to evaluate and monitor metabolic response to therapy in MM,
there are presently no studies that directly compare [18F]FDG-
PET/CT with WB-DWI or DCE-MRI. A recent systematic
review concluded that data on this topic are too heterogeneous,
with biased accrual, and lack an independent reference standard,
which also precluded a meta-analysis.70 Therefore, it remains
unclear which test may be best for response assessment. For rea-
sons that are presently not quite clear (the main hypothesis being
a low hexokinase-2 expression), a nonnegligible number (up to
11%) of MMpatients show no [18F]FDG-uptake71,72; MRI and
[11C]-Methionine-PETmay be helpful in this subset of cases.
Minimal residual disease (MRD) status is an important
predictor of clinical outcome in MM.73,74 Several highly sen-
sitive techniques such as ﬂow cytometry and next-generation
DNA sequencing have been introduced for detection of
MRD in the bone marrow.74–77 Outside of the bone marrow,
[18F]FDG-PET is regarded to be promising for the monitor-
ing of MM patients with MRD,78 even though a previous
study in 45 newly diagnosed MM or SM patients found no
relationship between [18F]FDG-PET/CT-based response and
MRD status, progression-free survival, or clinical response;
whereas DWI and DCE-MRI are largely untested in the set-
ting of MRD.79
Research Applications and Future Directions
for MRI and PET/MRI
The role of WB-MRI, and in particular, WB-DWI and DCE-
MRI for response assessment, monitoring, and prognostication in
myeloma remains unclear. In some studies, MRI could capture
treatment effects and separate responding from nonresponding
lesions using ADC measurements80,81 or Dixon-based bone sig-
nal fat fraction.81 For instance, Messiou et al observed signiﬁ-
cantly higher ADC values for active bone marrow disease than for
bone marrow in remission (761.2 vs. 601.8 × 10-6mm2s-1).80
On the other hand, DCE-MRI parameters, which capture differ-
ent aspects of microvascularity, showed prognostic potential in
patients with SM.82 However, in contrast to DWI-MRI, DCE-
MRI is not a whole-body technique and in general can only be
performed for a single anatomic region.
One of the main obstacles for generating reproducible
results and evidence on the value of WB-MRI for response
assessment and prognostication is the current lack of stan-
dardization, including the choice of MR sequences and their
interpretation. Messiou et al recently proposed the so-called
MY-RADS criteria that provide guidelines for initial assess-
ment and response assessment of myeloma patients.83 Similar
to PI-RADS for prostate cancer, DWI plays an important role
in MY-RADS. Speciﬁcally, an ADC increase of at least 40%
with a corresponding decrease in normalized high b-value sig-
nal intensity (relative to muscle tissue, which was used as ref-
erence tissue), or an ADC increase from below to above 1400
μm2/s indicates responding disease with a high likelihood,
also in the presence of morphologically stable disease.83 These
authors also proposed a scoring system for use in clinical
trials.
The combination of DWI and [18F]FDG-PET may prove
useful in myeloma, especially following treatment: Rasche et al84
reported that WB-DWI identiﬁed a higher number of lesions
than [18F]FDG-PET (21% vs. 6%), but not all PET-positive
lesions were visible on DWI, indicating complementary roles for
the two imaging tests; in addition, patients with positive ﬁndings
on both tests after completion of treatment had a particularly
poor prognosis84 (see Fig. 3). PET with other radiotracers, such
as [11C]methionine or [68Ga]Ga-Pentixafor21 may perhaps also
provide useful information.
Leukemia
Overview and Current Recommendations
for Imaging
Leukemia is the second largest family of hematological malig-
nancies after the lymphomas, and, depending on the subtype,
may show a considerable overlap of histological features with
the latter. The four main kinds of leukemia are, in the order
of their prevalence:
1. chronic lymphocytic leukemia (CLL; the most common
form, affecting mainly elderly patients),
2. acute myeloid leukemia (AML),
3. chronic myeloid leukemia (CML), and
4. acute lymphoblastic leukemia (ALL, the most common
form in pediatric patients).
Other notable subtypes include hairy cell leukemia (HCL),
acute promyelocytic leukemia (APML), and the extremely aggres-
sive and frequently therapy-refractory T-cell prolymphocytic leu-
kemia (T-PLL), the most common type of mature T-cell
leukemia, and the leukemia with the poorest prognosis.
Imaging has traditionally played a limited role in the
work-up of leukemias, with regard to detection, staging, and
response assessment. Imaging—typically plain ﬁlm radio-
graphs of the chest8 and rarely CT—are mostly used to rule
out complications such as lung involvement or infection, or a
mediastinal mass. Indeed, the only leukemia guideline to
mention cross-sectional imaging techniques is the Interna-
tional Workshop for Chronic Lymphocytic Leukemia
(iwCLL), which explicitly advises against the use of CT for
detection of enlarged lymph nodes and splenomegaly in rou-
tine clinical practice, suggesting that physical examination is
sufﬁcient for this task, and should be the basis of the Binet
and Rai staging systems, even though it has been reported
that patients with Rai stage 0 but abdominal disease
6
Journal of Magnetic Resonance Imaging
detectable by CT scans may have a more aggressive course.6
For CLL patients participating in clinical trials, on the other
hand, contrast-enhanced CT of the neck, chest, abdomen,
and pelvis is recommended by the iwCLL, both for staging
and treatment response assessment, using a slightly simpliﬁed
version of the Lugano criteria that rely on bidimensional mea-
surements of up to six enlarged lymph nodes, as well as the
vertical diameter of the spleen.6 Whole-body MRI is not rec-
ommended as an alternative to CT outside of clinical trials,
because according to the guidelines, it does not offer a clear
advantage over CT—the ability of MRI to evaluate bone
marrow directly is not addressed. [18F]FDG-PET is not rec-
ommended for routine evaluation of CLL, because the disease
shows low uptake in the majority of cases. The only excep-
tion is suspected Richter’s transformation into an aggressive
lymphoma, such as DLBCL.6
The clinical utility of MRI lies in the detection of bone
marrow abnormalities that are suspicious for leukemia in
adult and pediatric patients with unclear musculoskeletal
symptoms. These ﬁndings include replacement of the fatty
bone marrow by leukemic cells, leading to a decreased signal
on T1-weighted, increased signal on STIR, or an abnormal
enhancement pattern on contrast-enhanced fat-saturated
sequences. In children, the classic band-like abnormalities
along the metaphysis of long bones, especially at the level of
the knee or wrist, may be seen in ALL.85 PET/MRI, on the
other hand, has no real clinical justiﬁcation behind it at pre-
sent, but due to its reduced radiation dose (in comparison
with PET/CT), it may become more attractive with the use
of newer, non-FDG PET radiotracers.
Research Applications and Future Directions
for MRI and PET/MRI
Apart from the classic T1-weighted and STIR sequences that
are well established for visualization of the bone marrow, two
other MRI sequence types—particularly DCE-MRI, and
DWI and its variants—have been subject to research in adult
and pediatric leukemia patients.
A decade ago, Shih et al reported that bone marrow
angiogenesis, as assessed by two quantitative parameters
(pretherapeutic peak enhancement and amplitude) derived
from DCE-MRI, enables prediction of overall and disease-free
survival in AML patients who received induction chemother-
apy; in addition, higher peak enhancement was shown to be
an independent predictor for overall survival, with a hazard
ratio of 9.2.86 In a second study, the same author group
reported that a reduction in peak enhancement 7 days after
treatment was associated with a more favorable treatment out-
come in AML: 87% of patients with a decrease in peak
enhancement achieved complete remission, as compared with
71% with an increase in peak enhancement, and 80%
vs. 44% remained disease-free, respectively.87 However, no
further studies on DCE-MRI in AML or other leukemias
were performed, and so the technique was never implemented
in clinical practice.
Nishi et al were the ﬁrst to describe the successful
application of DWI to predict bone marrow inﬁltration in
pediatric patients with different leukemia subtypes, using the
clivus-to-pons signal intensity ratios.88 Cao et al reported the
successful use of DWI to capture treatment response in pedi-
atric ALL patients, based on normalization of ADC values
FIGURE 3: A 60-year-old patient with multiple myeloma. While DWI captures multiple focal lesions with restricted diffusivity in the
pelvic bones, [18F]FDG-PET captures just a single lesion with extension through the cortical bone into the soft tissues (blue arrows).
After treatment, [18F]FDG-PET shows complete remission in good accordance with clinical ﬁndings, whereas DWI shows residual
changes with increasing ADCs as a clear sign of treatment response; whether these DWI/ADC changes represent partial or complete
response is unclear. T1-weighted images of the spine show pathologically decreased signal with multiple focal lesions before as well
as after treatment, without any obvious changes.
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measured in the skull.89 Finally, Niu et al investigated the
predictive value of pretherapeutic intravoxel-incoherent
motion (IVIM) MRI—a variation of DWI that enables the
assessment of the perfusion component in addition to true
molecular diffusion—in patients with AML. Their results
suggested that true molecular diffusion (D) and the perfusion
fraction (f ) differ signiﬁcantly between AML patients achiev-
ing, and those not achieving, complete remission after induc-
tion chemotherapy.90
More recently, [68Ga]Ga-Pentixafor-PET/MRI with DWI
has been investigated in a small series of patients with CLL, to
determine whether this imaging technique can capture bone mar-
row involvement based on CXCR4 expression or diffusivity91 (see
Fig. 4). Here, [68Ga]Ga-Pentixafor uptake, which was signiﬁcantly
higher than in the two nonleukemic control groups, and ADC
values showed no signiﬁcant correlation, suggesting a complemen-
tary role for the two imaging tests. In addition, there was a signiﬁ-
cant negative correlation between ADCs and the white blood
cell count (r = –0.78), and ADCs and the lymphocyte percentage
(r = –0.81), but not between [68Ga]Ga-Pentixafor uptake and labo-
ratory ﬁndings in that study. The feasibility of [68Ga]Ga-
Pentixafor-PET has also been demonstrated for AML.22 Whether
the combination of DWI with [68Ga]Ga-Pentixafor is clinically
useful in the sense of providing a multimodal oncologic "signature"
for leukemias is yet to be determined. The two main arguments for
the use of [68Ga]Ga-Pentixafor-PET in CLL are that high CXCR4
expression is known to be associated with poor prognosis in CLL,92
and that—similar to myeloma—[68Ga]Ga-Pentixafor-PET might
enable the selection of patients for systemic treatment with [177Lu]
Pentixather. In this setting, ADCsmight serve as a surrogatemarker
for treatment response whose biologic correlate—ie, cell density—
is at least partly independent of CXCR4 expression.
The proliferation marker [18F]FLT, on the other hand,
is a promising PET tracer for acute leukemias, as it has been
shown to carry diagnostic as well as prognostic value in a
small number of studies.93,94 So far, only a combination of
[18F]FLT with dual-energy CT,95 but no combination with
MRI has been attempted.
Summary and Outlook
The role of WB-MRI and PET/MRI in hematological malig-
nancies is subject to intensive research. WB-MRI is already
recognized as a highly sensitive test for the assessment of mye-
loma, and endorsed by clinical guidelines, since it is the only
technique that can directly visualize bone marrow. For lym-
phoma, on the other hand, WB-MRI is presently not rec-
ommended by clinical guidelines, and is merely regarded as
an alternative technique to [18F]FDG-PET/CT when radia-
tion exposure is a concern, as for instance in pediatric
patients, or when CNS involvement is suspected. Despite
their high sensitivity, WB-MRI, and especially DWI, is cur-
rently not recommended in patients with non-FDG-avid lym-
phoma subtypes such as MALT lymphoma and SLL. Here,
FIGURE 4: A 70-year-old patient with chronic lymphocytic leukemia (CLL) with clearly increased CXCR4 expression in the entire
skeleton as well as axillary lymph nodes on [68Ga]Ga-Pentixafor-PET/MRI. DWI shows diffusion restriction within the bone marrow,
with high signal on the b-800 DWI and low signal on the ADC map. While this ﬁnding alone is unreliable for the diagnosis of bone
marrow involvement, the low signal on the T1-weighted image (T1w) that reﬂects the replacement of fatty bone marrow by leukemic
cells supports the diagnosis.
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active promotion by the MRI community is needed to raise
the awareness of clinicians with regard to the superiority of
WB-MRI with DWI over the standard test, CE-CT.
For response assessment, [18F]FDG-PET/CT is the
established imaging test for lymphoma, and is also gaining
momentum for this indication in myeloma. On the other
hand, the recently published MY-RADS guidelines propose
the use of WB-MRI with DWI for this purpose. Prospective
studies focusing on changes in clinical management and sur-
vival are required to generate evidence for the noninferiority
of advanced MRI techniques such as DWI, and possibly also
DCE-MRI.
If supported by sufﬁcient data, PET/MRI may be able to
establish itself as a uniformly applicable and truly multi-
parametric imaging test for hematological malignancies. In par-
ticular for leukemia and myeloma, the combination of PET with
non-FDG radiotracers (such as [68Ga]Ga-Pentixafor or [11C]
methionine) andWB-MRI has high potential.
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